Orion Corporation, Orion Pharma

🇫🇮Finland

Country: 🇫🇮Finland

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Inspiratory Flow Parameters of Easyhaler and Diskus Inhalers (SALIF)

Not Applicable

Completed

Conditions: Asthma
Chronic Obstructive Pulmonary Disease

Interventions: Device: Diskus inhaler
Device: Easyhaler type A
Device: Easyhaler type B

First Posted Date: 2011-08-26

Last Posted Date: 2012-02-03

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 227

Registration Number: NCT01424137

Locations: 🇪🇪
Tartu University Hospital, Lung Clinic, Tartu, Estonia
🇫🇮
Turku University Hospital, Turku, Finland
🇪🇪
Children's Clinic of Tartu, Allergy Centre, Tartu, Estonia

and more 2 locations

Phase I Pharmacokinetic Study (BF-BLOCK)

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: Budesonide/formoterol capsule.
Drug: Budesonide/formoterol capsule for oral adm.

First Posted Date: 2011-08-25

Last Posted Date: 2011-10-21

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 20

Registration Number: NCT01423305

Locations: 🇫🇮
Clinical Reseach Services Turku (CRST), Turku, Finland

Comparison of Budesonide and Formoterol Absorption From Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: Budesonide/formoterol Easyhaler 320/9 microg
Drug: Symbicort Turbuhaler forte

First Posted Date: 2011-07-01

Last Posted Date: 2011-12-22

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 74

Registration Number: NCT01386996

Locations: 🇫🇮
Orion Pharma Phase I Unit, Espoo, Finland

Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Placebo for ORM-12741
Drug: ORM-12741

First Posted Date: 2011-03-29

Last Posted Date: 2021-04-28

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 100

Registration Number: NCT01324518

Locations: 🇫🇮
Clinical Research Services Turku (CRST), Turku, Finland

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: ODM-201

First Posted Date: 2011-03-17

Last Posted Date: 2017-03-29

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 136

Registration Number: NCT01317641

Locations: 🇺🇸
Chesapeake Urology Research Associates, Baltimore, Maryland, United States
🇨🇿
Oddeleni Radiacni a Klinicke Onkologie Nemocnice Znojmo, Znojmo, Czech Republic
🇫🇮
Oulu University Hospital, Oulu, Finland

and more 20 locations

Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon

Phase 2

Terminated

Conditions: Raynaud's Phenomenon

Interventions: Drug: ORM-12471 30mg
Drug: placebo
Drug: ORM-12471

First Posted Date: 2011-03-15

Last Posted Date: 2014-06-27

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 15

Registration Number: NCT01315899

Locations: 🇬🇧
Salford Royal NHS foundation Trust, Salford, Greater Manchester, United Kingdom

Comparing Different Levodopa/Carbidopa/Entacapone Treatment Regimens

Phase 2

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Carbidopa

First Posted Date: 2011-02-15

Last Posted Date: 2011-09-12

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 27

Registration Number: NCT01296464

Locations: 🇫🇮
ODL Terveys Oy (ODL), Oulu, Finland
🇫🇮
Porin Lääkäritalo, Pori, Finland
🇫🇮
Kanta-Hämeen keskussairaala, Hämeenlinna, Finland

and more 2 locations

Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: Budesonide/formoterol 320/9 μg and 400/12 μg inhalers

First Posted Date: 2010-08-13

Last Posted Date: 2011-06-10

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 20

Registration Number: NCT01181063

Locations: 🇫🇮
Phase I Unit, Orion Pharma, Espoo, Finland

Pharmacokinetic Study of Spironolactone 25 mg, 50 mg and 100 mg Tablets

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Spironolactone

First Posted Date: 2010-03-09

Last Posted Date: 2010-05-10

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 14

Registration Number: NCT01083290

Locations: 🇮🇳
Accutest Research Laboratories (I) Pvt. Ltd., Mumbai, India

Levodopa Concentration Profile With Stalevo 75/125 mg

Phase 1

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Stalevo (levodopa/ carbidopa/ entacapone)
Drug: Sinemet (levodopa/carbidopa)

First Posted Date: 2010-02-18

Last Posted Date: 2010-08-13

Lead Sponsor: Orion Corporation, Orion Pharma

Target Recruit Count: 20

Registration Number: NCT01070628

Locations: 🇫🇮
Phase I Unit, Orion Pharma, Espoo, Finland

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy